Regulatory motifs in Chk1

Area of Science:

• Cellular Biology
• Molecular Biology
• Cancer Therapeutics

Background:

• Checkpoint kinase 1 (Chk1) is the key effector kinase regulating the G2 DNA damage checkpoint.
• Chk1 activation is critical for cell cycle arrest, allowing DNA repair following damage.
• Existing models suggest Chk1's C-terminal regulatory domain negatively controls its kinase domain, but this is debated.

Purpose of the Study:

• To investigate the role of previously uncharacterized domains in Chk1 regulation and activation.
• To elucidate the mechanisms underlying the dual positive and negative regulatory control exerted by Chk1's C-terminal domain.
• To identify novel therapeutic targets for Chk1-based anticancer drugs.

Main Methods:

• Analysis of Chk1 homologs, focusing on conserved domains including the kinase-associated 1 (KA1) domain and C-terminal extension (CTE) domain.
• Functional studies in fission yeast to assess the necessity of KA1 and CTE domains for Chk1 activation.
• Investigating Chk1 interactions with mediator proteins, such as Crb2 (homolog of human 53BP1).

Main Results:

• Chk1 homologs possess a conserved KA1 domain and a CTE domain, previously implicated in auto-inhibition and regulation.
• Both KA1 and CTE domains are essential for Chk1 activation in fission yeast, contrary to previous models of auto-inhibition.
• These domains mediate crucial intra- and intermolecular interactions, including binding to mediator proteins like Crb2.

Conclusions:

• The KA1 and CTE domains play critical roles in Chk1 activation by mediating interactions with mediator proteins.
• These findings resolve the paradox of the C-terminal domain exerting both positive and negative control over Chk1.
• The KA1 and CTE domains represent potential novel targets for developing Chk1 inhibitors as anticancer therapeutics, distinct from the ATP-binding pocket.